Your browser doesn't support javascript.
loading
Transcatheter aortic valve replacement for stenotic bicuspid aortic valves: Systematic review and meta analyses of observational studies.
Reddy, Gautam; Wang, Zhen; Nishimura, Rick A; Greason, Kevin L; Yoon, Sung-Han; Makkar, Raj R; Holmes, David R.
Afiliação
  • Reddy G; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
  • Wang Z; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
  • Nishimura RA; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
  • Greason KL; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
  • Yoon SH; Department of Cardiovascular Diseases, Cedars Sinai Medical Center, Los Angeles, California.
  • Makkar RR; Department of Cardiovascular Diseases, Cedars Sinai Medical Center, Los Angeles, California.
  • Holmes DR; Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Catheter Cardiovasc Interv ; 91(5): 975-983, 2018 04 01.
Article em En | MEDLINE | ID: mdl-28963771
ABSTRACT

OBJECTIVE:

The aim of this study was to perform a systematic review and meta-analyses of observational studies of transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve stenosis (BcAV).

BACKGROUND:

TAVR for BcAV stenosis has been associated with an increased incidence of paravalvular leaks, valve malposition, pacemaker placement and all-cause mortality. The conclusions drawn have been limited by small sample sizes. The use of TAVR for BcAV stenosis remains controversial.

METHODS:

We searched multiple databases from the inception of the databases through September 30, 2016 for studies of TAVR for BcAV stenosis. We included all observational studies with more than one patient and at least 1 month of outcomes.

RESULTS:

We analyzed 13 observational studies with 758 patients. Meta analyses showed device success rate of 95% [95% confidence interval (CI) 90.2% to 98.5%] and an early safety event in 16.9% [95% CI 12.2% to 22%]. At 30 days, moderate to severe paravalvular leak was seen in 12.2% [95% CI 3.1% to 24.8%] and new pacemaker implantation in 17.9% [95% CI 14.2% to 22%]. All-cause mortality was 3.7% [95% CI 2.1% to 5.6%], which should be viewed in the context of an STS PROM of 5.0%.

CONCLUSIONS:

This analysis suggests that TAVR for BcAV is not associated with excess mortality. The incidence of paravalvular leaks and pacemaker implant is increased compared to tricuspid aortic valve cohorts undergoing TAVR, and operators should weigh these potential complications against the clinical benefit provided by TAVR for BcAV patients at high risk for surgical valve replacement.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article